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xenotransplants from prepubertal boys: a 
three-case study
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KEY MESSAGE
Treatment of testis tissue from prepubertal boys with vascular endothelial growth factor (VEGF) before xenotransplantation 
resulted in higher vascularized transplants containing more intact seminiferous tubules and increased number of 
spermatogonia compared with controls. Therefore, VEGF may be considered as a potential candidate for improving the 
long-term efficiency of immature testis tissue transplantation.
ABSTRACT
Research question: Does recombinant human vascular endothelial growth factor (VEGF-165) improve the efficiency of human immature 
testis tissue (ITT) xenotransplantation?
Design: ITT fragments from three prepubertal boys were cultured for 5 days with VEGF-165 or without (control) before 
xenotransplantation into the testes of immunodeficient mice. Xenotransplants were recovered at 4 and 9 months post-transplantation 
and vascularization, seminiferous tubule integrity, number of spermatogonia and germ cell differentiation were evaluated by histology and 
immunohistochemistry.
Results: Transplants from donor 1 and donor 2 treated with VEGF demonstrated higher vascular surface (P = 0.004) and vessel density (P = 0.011) 
overall and contained more intact seminiferous tubules (P = 0.039) with time, compared with controls. The number of spermatogonia was increased 
over time (P < 0.001) irrespective of treatment and donor, whereas, for the VEGF-treated transplants, the increase was even higher over time 
(P = 0.020). At 9 months, spermatocytes were present in the xenotransplants, irrespective of treatment. No transplants could be recovered from 
donor 3, who had already received treatment with cyclosporine for aplastic anaemia before biopsy.
Conclusions: In-vitro pre-treatment of human prepubertal testis tissue with VEGF improved transplant vascularization in two out of three 
cases, resulting in improved seminiferous tubule integrity and spermatogonial survival during xenotransplantation. Although further studies are 
warranted, we suggest VEGF to be considered as a factor for improving the efficiency of immature testis tissue transplantation in the future.
2 RBMO  VOLUME 00  ISSUE 0  2019
INTRODUCTION
I mmature testis tissue (ITT) cryopreservation is the only fertility preservation option currently offered to prepubertal boys 
at risk of germ cell loss caused by 
gonadotoxic treatments (Picton et al., 
2015; Onofre et al., 2016). Promising 
technologies using testis tissue biopsies, 
containing spermatogonial stem cells 
(SSC), are being developed: in-vitro 
spermatogenesis, spermatogonial stem 
cell transplantation and testis tissue 
transplantation (TTT) (Keros et al., 2007; 
Ginsberg et al., 2010; Wyns et al., 2010; 
Clark et al., 2011; Sadri-Ardekani et al., 
2011; Sato et al., 2011; Goossens et al., 
2013; de Michele et al., 2017).
The advantage of TTT is that it enables 
the transfer of the SSCs within their 
natural environment, without disturbing 
the interactions between germ cells 
and supporting cells (Goossens et al., 
2013). In several non-primate species 
(Honaramooz et al., 2002; Schlatt 
et al., 2002; Shinohara et al., 2002; 
Oatley et al., 2005; Abrishami et al., 
2010; Reddy et al., 2012) and non-
human primates (Honaramooz et al., 
2004; Ehmcke et al., 2011; Liu et al., 
2016) xenotransplantation of ITT into 
immunodeficient mice led to generation 
of spermatozoa. Xenotransplantation 
of human ITT has not yet resulted 
in complete spermatogenesis (Wyns 
et al., 2008; Sato et al., 2010; Van 
Saen et al., 2011; 2013). Long-term 
survival of human ITT xenotransplants 
has been demonstrated but the low 
spermatogonial recovery, the presence 
of degenerated tubules and the lack of 
complete spermatogenesis are challenges 
that need to be overcome (Wyns et al., 
2008; Van Saen et al., 2011).
The survival of the transplants depends 
on the neovascularization and the 
establishment of a vascular system for 
sufficient blood supply between the 
transplant and the host. The availability of 
oxygen, nutrients and factors supporting 
cell survival, proliferation and maturation 
is critical and thus the period of 
ischaemic hypoxia during transplantation 
is crucial (Arregui et al., 2008).
Therefore, stimulating neovascularization 
in the transplants may improve transplant 
survival and germ cell proliferation and 
differentiation. Vascular endothelial 
growth factor (VEGF) is an angiogenesis-
inducing factor. The VEGF family, 
with five members (VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and placenta-derived 
growth factor) belongs to the vascular 
endothelium-specific growth factors, 
also including the angiopoietin family 
(Ang1, Ang2 and Ang3) and ephrin family 
(Ephrin-B2) (Gale and Yancopoulos, 
1999). As a highly potent stimulator 
of the vascular endothelium, VEGF 
promotes endothelial cell migration 
and proliferation, leading to the 
formation of new blood vessels either by 
vasculogenesis or angiogenic sprouting 
(Ferrara and Davis-Smyth, 1997; Risau, 
1997; Yancopoulos et al., 2000; Rafii and 
Lyden, 2003). Upregulated transcription 
of VEGF is caused by several factors, 
including hypoxia, cytokines and growth 
factors (Shweiki et al., 1992), and 
biological effects are mediated through 
binding to two receptor tyrosine kinases, 
VEGFR-1 and VEGFR-2 (Barleon et al., 
1996).
Administration of VEGF, either by culture 
of the tissue before transplantation or by 
hydrogel delivery, promoted angiogenesis, 
follicular survival and enhanced the 
function of ovarian tissue xenotransplants, 
including human (Shikanov et al., 2011; 
Labied et al., 2013; Wang et al., 2013; 
Henry et al., 2015; Langbeen et al., 2016; 
Tavana et al., 2016). A previous study 
on autotransplantation of mouse ITT 
revealed a positive short-term effect of 
VEGF on transplant neovascularization 
5 and 21 days post-transplantation 
(Poels et al., 2016), whereas the 
enhancement of germ cell survival has 
been demonstrated in several species, 
including mouse, pig and bovine 
(Schmidt et al., 2006; Caires et al., 2009, 
2012; Dores and Dobrinsky, 2014; Poels 
et al., 2016, Tian et al., 2016).
In the present study, the potential 
effect of in-vitro pre-treatment with 
VEGF on human prepubertal testis 
tissue xenotransplants in terms of 
vascularization, seminiferous tubule 
integrity, spermatogonial survival and 
differentiation over a medium (4 months) 
and long (9 months) period was 
investigated.
MATERIALS AND METHODS
Human tissue donors
The present study was carried out 
according to The Code of Ethics of the 
World Medical Association (Declaration 
of Helsinki). The experiments were 
approved by the internal review board of 
the Universitair Ziekenhuis Brussel (UZ 
Brussel) (reference number: 2004/17D on 
29 April 2004, reference number: 2015/
V3 on 28 January 2015 and reference 
number: 2017/061 on 22 March 2017).
Testis tissue biopsies were obtained from 
three prepubertal patients aged 3, 8 and 
9 years (further referred to as donor 
1, 2 and 3, respectively), after written 
informed consent was obtained from their 
parents. All patients underwent testicular 
tissue banking as part of their fertility 
preservation programme at the Centre 
for Reproductive Medicine of the UZ 
Brussel. Ninety per cent of the biopsy was 
stored for later fertility restoration, and 
10% was donated for research purposes. 
As donor 1 did not survive his disease, all 
cryopreserved material was donated for 
research. Donor 1 was diagnosed with a 
malignant disease (neuroblastoma) and 
had received treatment with carboplatin 
before the biopsy was taken. Donor 2 was 
also diagnosed with a malignant disease 
(Hodgkin's lymphoma) but the ITT biopsy 
was taken before the start of the treatment. 
Donor 3 had a non-malignant disorder 
(aplastic anaemia) and had received 
cyclosporine before the biopsy (TABLE 1).
Tissue preparation and in-vitro 
treatment with VEGF Cryopreserved 
ITT was thawed, as previously described 
(Van Saen et al., 2011), and cut into 
smaller fragments (1.0–1.5 mm3). Testis 
tissue fragments were placed in air-liquid 
interface culture (34°C and 5% CO2) on 
0.4-µm pore membrane inserts (Millicell 
Cell culture plate inserts; Sigma Aldrich, 
Bornem, Belgium). Fragments were 
cultured in Dulbecco's Modified Eagle 
Medium (DMEM) F-12 (Life Technologies, 
Thermo Fischer Scientific, Gent, 
Belgium) containing 10% human serum 
albumin (HSA) (Vitrolife, Göteborg, 
Sweden), 1% Penicillin-Streptomycin 
(Thermo Fischer Scientific, Gent, 
Belgium) and 100 ng/ml of recombinant 
human VEGF-165 (293-VE-010; R&D 
systems, Abingdon, UK) or without 
VEGF-165 (control) (FIGURE 1). Tissue 
culture was maintained for 5 days, with 
media change every 2 days (Caires et al., 
2009). Testis fragments were washed in 
DMEM before transplantation.
Intratesticular xenotransplantation
All experimental procedures were 
carried out according to the European 
Union Directive 2010/63/EU for animal 
experiments and approved by the 
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Animal Care and Use Committee of 
the Vrije Universiteit Brussel (VUB) on 
8 December 2014 (reference number: 
14-216-4). Twelve fragments of donor 1 
were immediately fixed after culture for 
immunohistochemical analysis (in-vitro 
study). In total, 64 ITT fragments were 
transplanted into the testes of 4–5-week-
old Swiss Nu/Nu mice (n = 48) (Charles 
River Laboratories, Saint-Germain-
Nuelles, France). More specifically, 
32 mice received a single ITT fragment 
from donor 1 in one testis and a frozen–
thawed testis tissue (Van Saen et al., 
2011) from 5–7-day old SV129 X C57BL 
green fluorescent protein (GFP+) mice 
(bred at the animal facility of the VUB) in 
the contralateral testis. The GFP+ mouse 
ITT served as a TTT control in this study 
to show that the transplantation process 
worked. All ITT fragments from donor 2 
(n = 16) and donor 3 (n = 16) were used 
for xenotransplantation. One human 
ITT fragment was transplanted into both 
testes of eight mice (TABLE 2).
Briefly, mice were anaesthetized by a 
single intraperitoneal injection (75 μl/10g 
of body weight) of a mixture of 0.1 mg/
ml medetomidine hydrochloride and 0.75 
mg/ml ketamine hydrochloride. After 
exteriorization of the mouse testis, a fine 
incision was made in the tunica albuginea 
and the transplant was inserted under 
the tunica, and the incision was closed 
using non-absorbable suture (U7003, 
10-0) (Ethicon, Instruvet, Beringen-Paal, 
Belgium).
Mice were housed individually in 
ventilated cages under a controlled 
environment of 14-h to 10-h light–dark 
cycle with access to sterilized diet and 
water. Cages were enriched with shelter, 
shredding materials and chewing toys.
Transplant recovery
Collection of mouse testes was 
carried out at 4 and 9 months post-
transplantation. After fixation, the 
testes were embedded in paraffin and 
cut into 5-μm-thick serial sections. 
Immunostaining for human-specific 
vimentin (M072501; Dako, Heverlee, 
Belgium) was carried out for every tenth 
section to localize the human testis 
tissue transplant. Similarly, staining for 
GFP (SC-9996) (Bioconnect, Huissen, 
Netherlands) was used to identify mouse 
GFP+ transplants.
Histology and immunohistochemistry
For haematoxylin-periodic acid Schiff 
(H/PAS) staining, sections were 
deparaffinized in xylene (2 × 5 min) and 
rehydrated in a graded alcohol series 
(2 × 100%, 90% and 70% isopropanol). 
After washing in distilled water (2 × 5 
min), sections were oxidized in periodic 
acid solution (VWR International) for 
5 min. After two more washing steps, 
slides were placed in Schiff's reagent 
(VWR International) for 15 min. Next, 
sections were washed in distilled water 
(2 × 5 min) and counterstained with 
haematoxylin.
TABLE 1 TESTIS TISSUE DONORS
Patient information Histology
Donor Age (years) Disease Treatment received before 
biopsy
Time between 
treatment and biopsy
Most advanced 
germ cell type
1 3 Neuroblastoma Carboplatin (1500 mg/ m2)
Cisplatin (320 mg/ m2)
Cyclophosphamide 
(4200 g/ m2), 
2 consecutive days / daily dose: 
1050 mg/m2 x 2 courses
VP16 (1400 mg/ m2)
Vincristine (12 mg/ m2)
63 days Spermatogonia
2 8 Hodgkin's lymphoma None - Spermatogonia
3 9 Aplastic anemia Cyclosporine (85 mg twice a day) 150 days Spermatogonia
Testis tissue 
from 
prepubertal boy
Mouse
testis
Testicular 
biopsy
Intratesticular 
xeno-
transplantation Transplant 
recovery 
Testis tissue 
culture
5 days 4 or 9 months
FIGURE 1 Experimental design. Frozen–thawed testis tissue fragments from three prepubertal boys were cultured as tissue explants with vascular 
endothelial growth factor (VEGF)-165 (100 ng/ml) or without VEGF-165 (control). After 5 days, testis fragments were transplanted into the testes of 
immunodeficient mice. Xenotransplants were recovered at 4 or 9 months post-transplantation.
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Immunohistochemistry was carried out 
for several markers (Supplementary 
TABLE). Sections were deparaffinized in 
xylene (3 × 10 min) and rehydrated in a 
graded alcohol series (2 × 100%, 90% 
and 70% isopropanol). After washing 
with either phosphate-buffered saline 
(PBS; Life-technologies, Gent, Belgium) 
or tris-buffered saline (TBS) with 0.05% 
Tween 20 (Sigma Aldrich) for 5 min, 
endogenous peroxidase activity was 
blocked by incubating the tissue sections 
with hydrogen peroxide (H2O2; diluted 
in methanol) for 30 min. After a washing 
step, antigen retrieval was carried out by 
incubating the slides in retrieval solution 
in a water bath (95°C). Next, slides 
were washed, and tissue sections were 
incubated with normal goat serum (Tebu-
bio, Boechout, Belgium) diluted in PBS 
or TBS with 5% bovine serum albumin 
(Sigma Aldrich). Primary antibodies were 
applied to the sections and incubated 
in a humidified chamber overnight. In 
general, human adult tissue sections 
from cadaver testes obtained from 
the autopsy service of the UZ Brussel, 
were used as positive controls. Only 
for the anti-Müllerian hormone (AMH) 
immunostaining, human prepubertal 
testis tissue sections from testis 
fragments donated for research were 
used, as AMH is not expressed in adult 
Sertoli cells. As negative controls, the 
first antibody was replaced by a mouse 
(sc2025) (Santa Cruz, Biotechnology, 
Heidelberg, Germany) or a rabbit 
(sc2027) (Santa Cruz) immunoglobulin 
G (IgG) isotype control. After three 
washing steps, sections were incubated 
with a peroxidase-labelled secondary 
antibody (Dako Real Envision Detection 
System; Dako). After 1 h of incubation 
and three washing steps, visualization 
with 3,3′- diaminobenzidine (Dako Real™ 
Envision™ Envision system; Dako) 
and counterstaining with haematoxylin 
followed.
Transplant vascularization
Von Willebrand factor (VWF), a 
multimeric plasma glycoprotein 
produced exclusively by endothelial cells 
(Jaffe et al., 1973) was used to detect 
blood vessels. The antibody used is 
human specific and therefore only blood 
vessels of human origin were detected. 
Sections from three different depths of 
each recovered transplant were used for 
assessment. Vascular surface, expressed 
as the percentage of total blood vessel 
surface towards the total surface of the 
transplant, and vessel density, as the ratio 
between total number of blood vessels 
and total surface area of the transplant, 
were calculated. Blood vessel surface, as 
the area enclosed by endothelial cells, 
and transplant surface, were calculated 
by morphometry with CELL F software 
(Olympus, Berchem, Belgium).
Seminiferous tubule integrity
Sections stained with H/PAS were 
used to evaluate tubular integrity. 
The percentage of intact tubules was 
calculated on sections for every 50 µm 
of each transplant. As intact tubules, we 
considered tubules with uninterrupted 
basement membrane, good adhesion of 
the seminiferous epithelial cells to each 
other and to the basement membrane 
and without any sign of degeneration, 
as previously described (Van Saen 
et al., 2011). Only round tubular cross 
sections were included in the analysis. 
As round tubule, we accepted tubules 
with diameter maximum 1.5 times of the 
perpendicular diameter.
Spermatogonial survival
The germ cell marker MAGE-A4 
was used to evaluate the survival 
of spermatogonia after the 5-day 
culture and at 4 and 9 months post-
transplantation. MAGE-A4 is expressed 
mainly by spermatogonia, but also by 
primary spermatocytes (Takahashi et al., 
1995); therefore, only the positive cells 
situated at the basement membrane 
were counted. The number of MAGE-A4 
positive cells per mm2 (MAGE-A4+ cells/
mm2) and the percentage of positive 
tubules were calculated on sections for 
every 50 µm of each transplant.
Germ cell differentiation
At 9 months post-transplantation, the 
level of differentiation was determined 
based on morphological assessment 
of different germ cell types in all 
seminiferous tubules on H/PAS stained 
sections. The percentage of tubules 
containing the most advanced germ 
cell type was calculated. Tubules were 
characterized as tubules with no germ 
cells, when Sertoli cells were only 
present; tubules with spermatogonia, 
when spermatogonia were identified 
as the most advanced germ cell type 
present; and tubules with spermatocytes, 
when spermatocytes were present. 
Meiotic activity in the transplants was 
confirmed by immunostaining for 
the expression of the meiotic marker 
BOLL. The presence of pachytene 
spermatocytes was further confirmed by 
the typical pattern of γH2XA expression 
and the staining of the sex body in the 
nucleus of the cells.
Niche maturation
Differentiation of SSCs is 
highly influenced by the niche 
microenvironment, with Sertoli cells 
playing a key role in the establishment 
and function of the niche. Sertoli cell 
maturation and function was qualitatively 
assessed by immunostaining for the 
expression of Sertoli cell markers, 
including AMH, androgen receptor 
(AR) (Sharpe et al., 2003) and inhibin A 
(INHA) (Andersson et al., 1998).
Mouse transplants
Sections from GFP+ mouse transplants 
were used for GFP immunostaining to 
determine the status of spermatogenesis.
Microscopy
All microscopic evaluations were carried 
out on an inverted light microscope 
(Olympus IX81). For the evaluations, 
whole cross sections of the human testis 
tissue transplants were analysed with the 
programme CELL F (Olympus, Berchem, 
Belgium).
Statistical analysis
RStudio 1.1.463 running on R version 
3.5.1 (RStudio, Boston, Massachusetts) 
was used for all statistical analysis. 
Fisher's exact test was used to compare 
recovery rates between VEGF-
treated and control transplants at 4 
and 9 months, respectively. When 
describing the transplant analysis, 
frequencies and percentages were 
used. For expressing relationships for 
vascularization, seminiferous tubule 
integrity, spermatogonial survival and 
differentiation of human spermatogonia 
between VEGF-treated transplants and 
controls, the linear mixed-effects model 
was used provided by the package 
lme4 (Bates et al., 2015) in R. The 
lme4 package in the CRAN repository 
is a package designed for fitting linear 
and generalized linear mixed-effects 
models. It provides functions for fitting 
and analysing mixed models for which 
we used the linear variant by using the 
lmer function. Each time six covariates 
(treatment [VEGF and control], time [4 
months versus 9 months], donor and 
possible interaction effects [treatment 
x time], [treatment x donor] and [time 
x donor]) were entered into the model. 
When the observation was measured only 
once (e.g. germ cell differentiation at 9 
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months), covariates related to time were 
not included. A random effect for the 
mouse was added in which the effect was 
measured multiple times. For estimating 
the degrees of freedom, Satterthwaite's 
approximation (Satterthwaite, 1946) 
was used for calculating an estimated 
test statistic for the covariates in the 
linear mixed-effects model. A multiple 
testing correction was carried out using 
Benjamini and Hochberg False Discovery 
Rate based on the number of statistical 
models used in this study (Benjamini 
and Hochberg, 1995; Walters, 2016). A 
Mann–Whitney test was carried out on 
the spermatogonial survival data during 
explant culture. To meet the assumptions 
of the statistical models (homogeneity 
of variance and normality of residuals), 
transformation was applied. All P- values 
were reported two-sided and P < 0.05 
was considered statistically significant. 
Graphs were prepared using GraphPad 
Prism 6 (La Jolla, CA, USA). Results were 
visualized using bar charts, representing 
the mean values and standard deviations 
of the complete dataset in which multiple 
repetitive measurements were present.
RESULTS
Transplant recovery
As shown in TABLE 2, at 4 months post-
transplantation, all transplants (15/15) 
could be recovered (100% recovery 
rate) for donor 1, whereas, for donor 2, 
the recovery rate was 83% (5/6). Nine 
months post-transplantation, 80% (12/15) 
of the transplants could be recovered 
for donor 1 and 75% (6/8) for donor 
2 (FIGURE 2A and FIGURE 2B). For donor 
3, none of the transplants could be 
recovered at any time point and thus no 
further analysis was conducted. Overall, 
the recovery rate at 4 months was 92% 
(11/12) for the VEGF-treated transplants 
and 100% (9/9) for the control, whereas, 
at 9 months, the recovery rate was 91% 
(10/11) and 67% (8/12) for VEGF-treated 
and control transplants, respectively. 
No statistical difference was observed 
between recovery of VEGF-treated 
transplants and controls at any time 
point. For the GFP+ mouse transplants, 
all transplants (15/15) could be recovered 
(100% recovery rate) at 4 months, 
whereas, at 9 months, the recovery rate 
was 93% (14/15) (TABLE 2 and FIGURE 2C 
and FIGURE 2D). Two mice dedicated to 
donor 1 and one mouse dedicated to 
donor 2 died before the time of analysis, 
and those transplants were not included.
Effect of VEGF on transplant 
vascularization
For donor 1, the vascular surface at 
4 months post-transplantation was 
0.38 ± 0.21% in the VEGF-treated 
transplants and 0.26 ± 0.11% in the 
controls, whereas, at 9 months post-
transplantation, it was 0.27 ± 0.14% 
and 0.18 ± 0.14%, respectively. For 
donor 2, the vascular surface at 4 
months was 0.32 ± 0.23% in the 
VEGF-treated transplants and 0.30 
± 0.13% in the controls, whereas, 
at 9 months, it was 0.35 ± 0.20% 
and 0.16 ± 0.07% respectively. The 
VEGF-treated transplants exhibited an 
increased vascular surface (P = 0.004) 
compared with the controls. Overall, 
the vascular surface was significantly 
reduced (P = 0.004) regardless of the 
treatment during the transplantation 
period. No statistically significant 
difference between donor 1 and donor 
2 was observed (FIGURE 3A, FIGURE 3C and 
FIGURE 3D).
The vessel density for donor 1 was 1.93 ± 
0.67 × 10−5 µm−2 for the VEGF-treated 
transplants and 1.74 ± 0.63 × 10−5 µm−2 
for the controls at 4 months post-
transplantation and 1.55 ± 0.43 × 10−5 
µm−2 and 1.05 ± 0.29 × 10−5 µm−2 at 9 
months, respectively. For donor 2, the 
vessel density was 1.96 ± 1.67 × 10−5 
µm−2 in the treated transplants and 
1.94 ± 0.79 × 10−5 µm−2 in the controls 
at 4 months and 1.76 ± 0.75 × 10−5 
µm−2 and 1.07 ± 0.32 × 10−5 µm−2 
at 9 months respectively. The VEGF-
treated transplants showed an increased 
vessel density (P = 0.011) compared 
with controls, whereas the vessel 
density was significantly reduced 
(P = 0.001) between 4 and 9 months 
post-transplantation, irrespective of 
C
A
B
D Mouse IgG
Mouse IgG
FIGURE 2 Intratesticular testis tissue transplant retrieval at 4 months post-transplantation. (A) Localization of human testis tissue transplant 
(vimentin+) within the mouse testis (vimentin–) by vimentin immunostaining; (B) Magnified image of the recovered human testis tissue transplant 
(arrows indicate germ cells). Mouse IgG isotype control as negative control (human prepubertal testis tissue); (C) Localization of mouse testis 
tissue transplant (green fluorescent protein [GFP]+) in Swiss Nu/Nu mouse testis (GFP–) by GFP immunostaining; and (D) magnification of the 
recovered mouse testis tissue transplant (arrowheads indicate spermatozoa). Mouse IgG isotype control as negative control (mouse adult testis 
tissue).
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treatment and donor. Similar to the 
vessel surface, the vessel density was 
not statistically different between donors 
(FIGURE 3B).
Effect of VEGF on seminiferous tubule 
integrity
For donor 1, the percentage of intact 
tubules at 4 months after transplantation 
was 79 ± 13% in the VEGF-treated group 
and 76 ± 14% in the control group, 
whereas, at 9 months, it was 74 ± 12% 
and 68 ± 11%, respectively. For donor 
FIGURE 3 Effect of VEGF on transplant vascularization. (A) Vascular surface (%) in transplants from donor 1 and donor 2 at 4 and 9 months 
post-transplantation. Main effect: treatment- positive (P = 0.004); main effect: time- negative (P = 0.004); main effect: donor- not significant); (B) 
Vessel density (µm−2) in transplants from donor 1 and donor 2 at 4 and 9 months post-transplantation. Main effect: treatment- positive (P = 0.011); 
main effect: time- negative (P = 0.001); main effect: donor- not significant; (C) Representative immunostaining for the detection of blood vessels 
by von Willebrand factor (VWF) antibody in VEGF-treated transplant from donor 2 at 4 months post-transplantation; and (D) in human adult testis 
tissue serving as control for immunostaining. Arrows indicate vessels stained positive for VWF. Mouse IgG isotype control as negative control 
(human adult testis tissue). Data shown as mean ± SD.
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2, the percentage of intact tubules was 
79 ± 14% in the VEGF-treated group 
and 78 ± 18% in the control group 
at 4 months post-transplantation and 
78 ± 19% and 61 ± 15% at 9 months 
post-transplantation, respectively. 
During the transplantation period, a 
deterioration of the seminiferous tubule 
integrity was apparent for all transplants 
(P < 0.001). However, VEGF treatment 
demonstrated a significant positive effect 
on the integrity of seminiferous tubules 
in time (P = 0.039). Again, no difference 
was observed between the two donors 
(FIGURE 4A).
Effect of VEGF on spermatogonial 
survival
Evaluation of the effect of VEGF on the 
survival of spermatogonia during explant 
culture was only possible for donor 1. 
After 5 days in culture, the number of 
MAGE-A4+ cells was 7.5 ± 5.8 cells/mm2 
in the VEGF-treated fragments and 3.4 ± 
1.3 MAGE-A4+ cells/mm2 in the control 
fragments (FIGURE 5A). Also, 32 ± 19% of 
the seminiferous tubules were positive 
for MAGE-A4 cells in the VEGF-treated 
fragments and 16 ± 11% in the controls 
(FIGURE 5B). Overall, the treatment with 
VEGF did not significantly improve 
the survival of MAGE-A4+ cells during 
culture.
At 4 months post-transplantation, 
VEGF-treated transplants from donor 
1 contained 0.4 ± 0.9 MAGE-A4+ 
cells/mm2 and the controls 0.5 ± 0.8 
MAGE-A4+ cells/mm2, whereas, at 9 
months post-transplantation, transplants 
contained 2.5 ± 2.5 and 1.6 ± 1.9 
MAGE-A4+ cells/mm2, respectively. 
For donor 2, VEGF-treated transplants 
contained 18.8 ± 13.2 MAGE-A4+ 
cells/mm2 and the controls 13.7 ± 8.3 
MAGE-A4+ cells/mm2 at 4 months and 
43.4 ± 23.4 and 28.7 ± 9.2 MAGE-A4+ 
cells/mm2 at 9 months, respectively. 
Overall, the number of spermatogonia 
was increased over time (P < 0.001) 
irrespective of treatment and donor. 
Whereas, for the VEGF-treated 
transplants, the increase was even higher 
over time (P = 0.020). For donor 2, the 
increase in the number of spermatogonia 
due to the treatment and over time 
was even greater (P < 0.001 and P < 
0.002, respectively). The number of 
spermatogonia between the two donors, 
however, differed significantly (P < 0.001) 
(FIGURE 5A).
The percentage of MAGE-A4+ tubules 
for donor 1 was 2.39 ± 3.22% in the 
VEGF-treated transplants and 3.22 ± 
4.27% in the controls at 4 months and 
8.16 ± 6.74 % and 7.11 ± 11.54% at 9 
months, respectively. For donor 2, at 4 
months post-transplantation, 53.32 ± 
24.46% of the tubules in VEGF-treated 
transplants contained spermatogonia 
and 46.70 ± 21.90% of the tubules in 
the controls, whereas, at 9 months, the 
percentages were 79.08 ± 23.55% and 
73.37 ± 16.55%, respectively. During the 
transplantation period, the percentage 
of MAGE-A4+ tubules increased over 
time (P < 0.001) in both groups and 
for both donors. The percentage 
increase of MAGE-A4+ tubules in the 
VEGF-treated transplants from donor 
2, however, was even greater than 
for donor 1 (P = 0.035). Overall, a 
significant difference in the percentage 
of MAGE-A4+ tubules was observed 
between the two donors (P < 0.001) 
(FIGURE 5B).
Effect of VEGF on the differentiation 
of human spermatogonia
Histological analysis of the ITT from 
both donors at the time the biopsy 
was taken revealed that spermatogonia 
were the most advanced germ cell type 
present (FIGURE 6A). At 4 months post-
transplantation, spermatogonia were still 
the most advanced germ cells detected 
in the transplants from both donors, 
irrespective of treatment. At 9 months 
post-transplantation, spermatocytes 
were present in both VEGF-treated and 
control transplants (FIGURE 6A). More 
specifically, for donor 1, the percentage 
of tubules containing spermatocytes 
was 0.16 ± 0.54% in the VEGF-treated 
transplants and 0.07 ± 0.38% in the 
control group, whereas the percentage 
of tubules with spermatogonia was 7.72 
± 6.01% and 7.04 ± 11.50%, respectively. 
The percentages of tubules lacking 
germ cells were similar (92.12 ± 6.13% 
versus 92.88 ± 11.54%). For donor 2, 
the percentage of tubules containing 
spermatocytes was 6.79 ± 6.89% in the 
VEGF-treated transplants and 3.36 ± 
4.43% in the control group, whereas 
the percentage of tubules containing 
spermatogonia was 79.35 ± 10.53% 
and 70.46 ± 18.34%, respectively. The 
percentages of tubules without germ 
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FIGURE 4 Effect of VEGF on seminiferous tubule integrity. Percentage of intact seminiferous tubules in transplants from donor 1 and donor 2 
at 4 and 9 months post-transplantation. Main effect: treatment- not significant; main effect: time- negative (P < 0.001); main effect: donor- not 
significant; interaction effect: treatment x time- positive (P = 0.039); interaction effect: treatment x donor- not significant. Data shown as mean ± 
SD.
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cells was 13.87 ± 12.70% in the treated 
transplants and 26.18 ± 18.92% in the 
control group. In general, the distribution 
of tubules containing spermatocytes, 
spermatogonia and no germ cells differed 
significantly between donor 1 and donor 
2 (P < 0.001). Adjusting for this variable, 
VEGF-treated transplants from donor 
2 had a higher percentage of tubules 
containing spermatocytes (P < 0.001) 
and a higher number of spermatogonia 
(P = 0.019). Additionally, within the 
VEGF-treated transplants, the percentage 
of tubules without germ cells was 
decreased to a greater extent in donor 2 
than in donor 1 (P = 0.001) (FIGURE 6B).
Meiotic activity was confirmed by 
immunostaining for the meiotic 
marker BOLL (FIGURE 6A). Expression 
of BOLL, although faint, was detected 
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FIGURE 5 Effect of VEGF on spermatogonial survival and proliferation. (A) Number of MAGE-A4+ cells/mm2 in testis tissue fragments after 
culture for 5 days and in transplants from donor 1 and in transplants from donor 2 at 4 and 9 months post-transplantation. Main effect: treatment- 
not significant; main effect: time- positive (P < 0.001); main effect: donor- significant (P < 0.001); interaction effect- treatment x time- positive 
(P = 0.020); interaction effect: treatment x donor- significant (P < 0.001); interaction effect: time x donor- significant (P = 0.002); (B) percentage 
of MAGE-A4+ tubules in testis tissue fragments after culture and in transplants from donor 1 and in transplants from donor 2 at 4 and 9 months 
post-transplantation. Main effect: treatment- not significant; main effect: time- positive (P < 0.001); main effect: donor- significant (P < 0.001); 
interaction effect: treatment x donor- significant (P = 0.035); (C) testicular tissue containing MAGE-A4+ and MAGE-A4– tubules from donor 1 and 
(D) from donor 2, in VEGF-treated transplants at 9 months post-transplantation. Mouse immunoglobulin IgG isotype control as negative control 
(human prepubertal testis tissue). Data shown as mean ± SD.
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FIGURE 6 Effect of VEGF on the differentiation of human spermatogonia. (A) Spermatogonia were the most advanced germ cells present in fresh 
immature testis tissue from both donors. At 9 months post-transplantation, spermatocytes were morphologically identified on H/PAS stained 
sections in both VEGF-treated and control transplants. BOLL expression, although faint, confirmed the meiotic activity in the xenotransplants. 
Arrowheads indicate spermatogonia; arrows indicate spermatocytes. PC, positive control for BOLL antibody (human adult testis tissue). Orange 
arrows indicate late spermatocytes with strong BOLL expression; blue arrows indicate early spermatocytes with faint BOLL expression. Mouse IgG 
isotype control as negative control (human adult testis tissue); (B) Distribution of the different cell types in transplants from donor 1 and donor 2 
at 9 months post-transplantation. (1) Modelling ‘No germ cells’. Main effect: treatment- not significant; main effect: donor- significant (P < 0.001); 
interaction effect: treatment x donor- significant (P = 0.001); (2) Modelling ‘Spermatogonia’. Main effect: treatment- not significant; main 
effect: donor- significant (P < 0.001); interaction effect: treatment x donor- significant (P = 0.019); (3) Modelling ‘Spermatocytes’. Main effect: 
treatment- not significant; main effect: donor- significant (P < 0.001); interaction effect: treatment x donor- significant (P < 0.001); (C) Pachytene 
spermatocytes identified by the typical pattern of γH2XA expression in VEGF-treated transplants from donor 2 at 9 months. Mouse IgG isotype 
control as negative control (human adult testis tissue).
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in both VEGF-treated and control 
transplants. The presence of pachytene 
spermatocytes as the most advanced 
germ cell stage was confirmed by the 
typical pattern of γH2XA expression 
during spermatogenesis (FIGURE 6C).
All mouse transplants showed complete 
spermatogenesis at 4 and 9 months post-
transplantation (FIGURE 2C and FIGURE 2D).
Niche maturation
The expression of markers for Sertoli cell 
maturation and functionality (AMH, AR and 
INHA) did not differ significantly between 
VEGF-treated transplants and controls 
from both donors. In the transplants 
recovered after 4 and 9 months, AMH was 
expressed by Sertoli cells. At 9 months, 
some neighbouring tubules demonstrated 
different intensities of AMH expression. 
Tubules containing more spermatogonia 
and spermatocytes exhibited lower 
intensity of AMH compared with tubules 
with less spermatogonia or without 
spermatocytes indicating a different level of 
maturation. INHA expression was observed 
in all Sertoli cells. AR was observed in 
most Sertoli cells and in the interstitium 
(FIGURE 7). At the time of the biopsy (fresh 
tissue) compared with at 9 months, the 
expression of AMH was more intense 
whereas AR was observed in fewer Sertoli 
cells. INHA expression in Sertoli cells was 
denser.
DISCUSSION
In this study, the effect of VEGF 
on human prepubertal testis tissue 
xenotransplants was evaluated. After 
pre-treatment of ITT with VEGF, an 
overall enhancement of vascularization 
was observed, improvement of 
seminiferous tubule integrity, increase 
in the number of spermatogonia and 
the number of seminiferous tubules 
containing spermatogonia. The results 
were slightly variable between donors 
based on the time the testicular biopsy 
was taken (donor age, before or after 
the gonadotoxic treatment). Overall, 
during the xenotransplantation period, a 
deterioration of the vascular surface and 
seminiferous tubule integrity, an increase 
of the number of spermatogonia, and 
the number of tubules containing 
spermatogonia was observed in the 
transplants from both donors irrespective 
of treatment.
Our data show that VEGF had a 
profound effect on the vascular surface 
and vessel density of the transplants 
from both donor 1 and donor 2. In a 
previous study, mouse testis transplants 
supplemented with alginate-VEGF 
nanoparticles showed a significantly 
higher vascular surface at 5 and 21 
days post-transplantation (Poels et 
al., 2016). Furthermore, the blockage 
of the VEGF/VEGFR2 pathway by 
daily exogenous administration of the 
SU5416 antagonist led to disruption 
of angiogenesis and a substantial 
reduction of the number of blood 
vessels in regenerated mouse testis 
tissue (Tian et al., 2016). Other studies, 
however, reported no considerable 
differences in the formation of blood 
vessels in the presence of exogenous 
recombinant mouse VEGF-164 in bovine 
xenotransplants 6 or 8 weeks after 
transplantation (Schmidt et al., 2006; 
Caires et al., 2009) or recombinant 
human VEGF-165 in de-novo formed 
testis tissues from piglets after 3 
months (Dores and Dobrinski, 2014). 
Assessment of seminiferous tubule 
integrity revealed a considerable 
increase of intact seminiferous tubules 
in the VEGF-treated transplants over 
time. The more efficient vascularization 
of these transplants compared with 
the controls may have resulted in 
the improved preservation of intact 
tubules and seminiferous epithelium, 
a prerequisite for the establishment 
of the microenvironment for SSC 
maintenance, germ cell survival, 
proliferation and further differentiation 
(Oatley and Brinster, 2012). A 
tendency for better tubular integrity 
has been reported in mouse testis 
tissue transplants when tissue was 
embedded in hydrogel loaded with 
VEGF nanoparticles. The beneficial 
effect, however, was transient as it was 
present at 5 but not at 21 days post-
transplantation (Poels et al., 2016).
Vascular endothelial growth factor has 
been proposed as a regulator of germ 
cell survival and proliferation. The data 
obtained show that pre-treatment 
of human ITT with VEGF resulted in 
better spermatogonial survival in time. 
Previously, culture of bovine testis tissue 
with VEGF stimulated the expression of 
genes that prevent germ cell death (BCL2 
family) (Caires et al., 2009). Additionally, 
an upregulation of the germ cell specific 
marker MVH was observed in VEGF-
treated mouse testis tissue after ectopic 
transplantation, and an upregulation of 
c-Fos and Cyclin D1, which are involved 
in germ cell proliferation, has been 
reported in-vitro 24 and 48 h after 
VEGF stimulation (Tian et al., 2016). In 
our study, no significant difference was 
observed in germ cell survival between 
the VEGF-treated fragments and the 
controls after 5 days in culture. During 
transplantation of ITT, it is known that a 
substantial number of spermatogonia is 
lost irrespective of the transplantation 
site or the cryopreservation protocol 
(Wyns et al, 2007; Van Saen et al., 2009; 
Jahnukainen et al., 2012). The data we 
obtained from donor 1 demonstrated a 
lower number of spermatogonia after 
transplantation compared with their 
number just after culture, regardless of 
treatment.
The notable differences observed in 
the number of spermatogonia between 
the two donors could be due to their 
age difference, as spermatogonial 
quantity in human prepubertal testes 
is age related (Masliukaite et al., 2016). 
Additionally, treatment with carboplatin 
before the time of the testis biopsy for 
donor 1 could have contributed to the 
low germ cell number. Carboplatin is a 
platinum agent commonly used to treat 
childhood cancer and is considered to 
cause azoospermia with moderate to 
high risk (Trottmann et al., 2007). During 
the study, none of the transplanted 
ITT fragments from donor 3 were 
retrieved at any time point. Donor 3 
was diagnosed with aplastic anaemia 
and had treatment with cyclosporine. 
Cyclosporine is a calcineurin inhibitor 
and acts as immunosuppressant 
(Northrop et al., 1994; Rao and 
Hogan, 1997). In cases of solid organ 
transplantations in patients treated with 
cyclosporine, endothelial cell damage 
and impairment of their functionality has 
been observed (Rodrigues-Diez et al. 
2016). Moreover, cyclosporine prevented 
the migration of primary endothelial cells 
and angiogenesis induced by exogenous 
VEGF (Hernández et al., 2001) and had 
a toxic effect on vascular smooth muscle 
cells (Amador et al., 2015). Therefore, 
we hypothesize that the treatment 
of donor 3 with cyclosporine led to 
destruction of the function and migratory 
capacity of endothelial cells, resulting 
in reduced revascularization capability 
of the grafts and sequential loss. The 
above cases stress the importance of 
the timing a testicular biopsy should 
be taken from a prepubertal boy, as 
previous treatment with gonadotoxic 
regimens may compromise the viability 
12 RBMO  VOLUME 00  ISSUE 0  2019
of the transplants, quality, or both, and 
the number of germ cells in a future ITT 
auto-transplantation.
In the present study, pachytene 
spermatocytes were observed at 9 
months post-transplantation in the 
transplants from both donors, regardless 
of treatment. The expression pattern of 
γH2AX, that in human adult seminiferous 
epithelium follows a similar distribution to 
that found in rodents (Blanco-Rodriguez, 
2009), with the staining of sex body 
evident at pachytene stage, confirmed 
their presence. Meiotic activity of 
the germ cells in the transplants was 
confirmed by immunostaining for the 
meiotic marker BOLL. The expression 
was localized at the cytoplasm of 
spermatocytes but also at the nucleus of 
spermatogonia, as described before (Van 
Saen et al., 2011), but not in all germ 
cells that morphologically resembled 
spermatocytes. The faint expression 
is possibly reflecting the initiation of 
the protein expression. Interestingly, 
VEGF-treated transplants from donor 
2 contained more seminiferous 
tubules with spermatocytes compared 
with controls. Although it has been 
suggested that VEGF may promote 
germ cell differentiation (Schmidt et al., 
2006), the observed increase could 
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FIGURE 7 Sertoli cell maturation and functionality in fresh testis tissue and transplants treated with VEGF at 9 months post-transplantation. Anti-
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also be due to the higher number of 
tubules with spermatogonia in the 
VEGF-treated transplants and their 
further differentiation. Complete 
spermatogenesis in human ITT 
xenotransplants has not yet been 
reported. Spermatogenic cells up to 
pachytene spermatocytes were observed 
in ITT transplanted into the scrotum 
(Wyns et al., 2008) or under the dorsal 
skin of immunodeficient mice (Sato et al., 
2010). Previous studies in our laboratory 
have demonstrated differentiation up 
to secondary spermatocytes in ITT 
transplanted into the mouse testicular 
parenchyma (Van Saen et al., 2011; 
2013). ITT xenotransplants from both 
human and common marmoset have 
been characterized by spermatogenic 
arrest at pachytene stage (Wistuba 
et al., 2004, Wyns et al., 2008; Sato 
et al., 2010; Van Saen et al., 2011). 
Although accelerated maturation of 
primate testis tissue xenotransplants in 
mice has been reported (Honaramooz 
et al., 2004; Liu et al., 2016), the short 
lifespan of immunodeficient mice that 
we are currently using as animal model 
for the xenotransplantation experiments 
could be a limiting factor for successful 
completion of spermatogenesis. Humans 
have a longer prepubertal period, as they 
do not become capable of producing 
mature sperm until around the age of 12 
years, compared with the other species 
that have been successfully used so far. 
Also, although the functionality of Sertoli 
cells in human ITT xenotransplants 
was confirmed at 9 months post-
transplantation, the expression of AMH 
indicates the not fully matured status. 
Initiation of spermatogenesis is advanced 
after xenotransplantation; however, the 
time required for full maturation might 
be longer than the lifespan of a mouse.
Further research is necessary to 
improve germ cell differentiation in 
human prepubertal xenotransplants. 
Initiation and maintenance of 
spermatogenesis is highly dependent 
on interactions between hormones of 
the hypothalamic–pituitary–gonadal 
axis (Sofikitis et al., 2008). Although 
exogenous gonadotrophin administration 
in equine and monkey xenotransplants 
resulted in post-meiotic differentiation 
(Rathi et al., 2006; 2008), subcutaneous 
administration of recombinant human 
FSH did not result in the complete 
spermatogenesis in human ITT 
xenotransplants (Van Saen et al., 2013). 
Hypoxia-induced VEGF production 
is known to stimulate testosterone 
release in Leydig cells through binding 
to VEGFR-1 and VEGFR-2 (Ergun et al., 
1997; Hwang et al., 2007). Although the 
distinct role of FSH and testosterone 
in spermatogenesis has been a matter 
of controversy (Vigier et al., 2004), the 
presence of testosterone is critical for 
male fertility, and spermatogenesis does 
not proceed beyond meiosis in the 
absence of testosterone or the androgen 
receptor (Sharpe, 1994). The effect of 
exogenous testosterone on human ITT 
xenotransplants has been studied but the 
short evaluation point (5 days) did not 
allow any observations to be made on the 
potential differentiation of spermatogonia 
(Poels et al., 2014).
VEGF is one of the numerous paracrine 
factors secreted by mesenchymal 
stem cells (MSC), together with other 
angiogenic and proliferative factors, 
anti-inflammatory cytokines and anti-
apoptotic molecules. The ability of 
MSCs to migrate to sites of tissue injury 
promoting the survival and recovery 
of injured cells, repair and protection 
of damaged tissue makes them ideal 
candidates for regenerative medicine 
(Mackenzie and Flake, 2001; Wu 
et al., 2003; Uccelli et al., 2008; Feng 
et al., 2011). Co-transplantation of ITT 
with MSCs could be an alternative 
strategy to improve the efficacy of the 
transplantation procedure in future 
experiments.
Unfortunately, studies using human ITT 
are limited owing to the scarcity of the 
tissue for research purposes. Moreover, 
the small volume of each biopsy does 
not permit the simultaneous evaluation 
of other factors or conditions and the 
heterogeneity in the age of the donors 
and the treatment they may have 
received before testicular biopsy limits 
the size of a study.
In conclusion, the findings from the 
present study suggest that culture 
of human ITT with 100 ng/ml of 
recombinant human VEGF-165 for 
5 days improves vascularization, 
seminiferous tubule integrity and 
spermatogonial survival during 
long-term xenotransplantation in testis 
tissue from boys who did not receive 
cyclosporine treatment before the 
biopsy. To the best of our knowledge, 
this is the first study investigating the 
potential effect of VEGF on human ITT 
xenotransplants and, although further 
studies are required, VEGF may be 
considered as a potential candidate for 
improving the long-term efficiency of 
ITT transplantation.
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